Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera

NCT04057040 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.

NCT NCT04057040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04057040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera
Lead sponsor
Protagonist Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2019
Completion date
June 17, 2024
Enrollment
70 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera